The extended hold strategy If standard hold times of 2-3 minutes produce mediocre results, gradually extend to 5 minutes, then 7, then 10
What the research shows about GLP-1 medications: According to a study published in the New England Journal of Medicine (STEP-1 trial), participants receiving once-weekly semaglutide 2.4 mg plus lifestyle intervention experienced a mean weight loss of 14.9% from baseline over 68 weeks, compared with 2.4% for placebo plus lifestyle intervention
First, purity improved significantly over time
Hemoglobin A1c reduction with the GLP-1 receptor agonist semaglutide is independent of baseline eGFR: Post hoc analysis of the SUSTAIN and PIONEER programs
Heavy compound movements performed with adequate rest periods should form the foundation of your training, with higher-rep accessory work used judiciously
Our protocol integrates laboratory medicine, body composition analysis, and metabolic coaching to maximize safety and outcomes. Before starting GLP-1 therapy, we recommend a comprehensive metabolic workup that includes: Fasting glucose and insulin: Establishes baseline glucose control and HOMA-IR (insulin resistance index) HbA1c: 3-month glucose average
